(→Others) |
(There you go.) |
||
Line 80: | Line 80: | ||
:Cyprodime - Selective μ opioid antagonist with no affinity for κ or δ receptors | :Cyprodime - Selective μ opioid antagonist with no affinity for κ or δ receptors | ||
:Samidorphan - selective μ antagonist. potential for addiction treatment. | :Samidorphan - selective μ antagonist. potential for addiction treatment. | ||
+ | |||
+ | == Benzomorphans == | ||
+ | |||
+ | :Butinazocine - Benzomorphan opioid that was never marketed. | ||
+ | :Carbazocine - Benzomorphan opioid that was never marketed. | ||
+ | :Etazocine - Partial opioid agonist with mixed ant.-ag. effects. low potency | ||
+ | :Ethylketocyclozocine - Partial opioid agonist with mixed ant.-ag. effects. | ||
+ | :Ibazocine - Benzomorphan opioid that was never marketed. | ||
+ | :Moxazocine - 10x potency of Morphine, partial/mixed ant.-ag. | ||
+ | :Tonazocine - Partial agonist at μ & δ, no adverse effects on breathing. | ||
+ | :Volazocine - Benzomorphan opioid that was never marketed. | ||
+ | :Fluorophen - Radioligand, full μ agonist (6x M) & lower affinity for δ. | ||
+ | :Zenazocine - Partial agonist at μ & δ. | ||
+ | :Eptazocine - Japanese κ agonist & μ antagonist | ||
+ | :Pentazocine - Mixed ant.-ag. (-) is the κ agonist side, the (+) displays 10x the affinity for sigma receptors. NO μ agonism | ||
+ | :Phenazocine - Related to ^ but stronger analgesic, 4x potency of M | ||
+ | :Cyclazocine - Mixed ant.-ag. | ||
+ | :Dezocine - Mixed ant.-ag. with high κ antagonism. Low dose=euphoria (μ) High dose=dysphoria (κ). Weird structure | ||
+ | :8-Carboxamidocyclazocine (8-CAC) - κ & μ agonist, long duration. | ||
+ | :Bremazocine - κ agonist related to Pentazocine | ||
+ | :Metazocine - Analgesic; mixed ant.-ag. at μ, activity also at κ and sigma | ||
+ | :Alazocine - σ1 agonist, κ opioid agonist & slight NMDA antagonist | ||
== 4-Phenylpiperidines == | == 4-Phenylpiperidines == | ||
Line 98: | Line 120: | ||
== Ketobemidones == | == Ketobemidones == | ||
− | :Acetoxyketobemidone - Unschedualed analogue of | + | :Acetoxyketobemidone - Unschedualed analogue of Ketobemidone. |
− | :Bemidone - Analogue of Pethidine but significantly less potent, however it has NMDA antagonism like | + | :Bemidone - Analogue of Pethidine but significantly less potent, however it has NMDA antagonism like Ketobemidone. |
− | :Ketobemidone - μ opioid antagonist & NMDA antagonist. More addictive than | + | :Ketobemidone - μ opioid antagonist & NMDA antagonist. More addictive than Morphine. |
== Others == | == Others == | ||
Line 191: | Line 213: | ||
:3-HO-TCP - PCP analogue. More glutamergic than the PCP analogue. | :3-HO-TCP - PCP analogue. More glutamergic than the PCP analogue. | ||
− | |||
:3-HO-BCP - substitutes for both cocaine and morphine at ~5mg (made-up) | :3-HO-BCP - substitutes for both cocaine and morphine at ~5mg (made-up) | ||
− | |||
:AD-1211 - Structure looks unrelated to /most/ other opioid drugs. Mixed Agonist-antagonist at opioid recepts similar to pentazocine. Little to no developement of tolerance/dependence in animal studies. | :AD-1211 - Structure looks unrelated to /most/ other opioid drugs. Mixed Agonist-antagonist at opioid recepts similar to pentazocine. Little to no developement of tolerance/dependence in animal studies. | ||
− | |||
:AH-7921 - Selective μ agonist, with 80% potency of M. distributed as an RC, TRs show that it has very little euphoria, indicating euphoria comes from somewhere else. Perhaps sigma? Other opioids are heavily potentiated by it. Perhaps μ agonism is purely analgesic and high comes from a combination of μ & δ with each multiplying the affect of the other. This indicates ultimate opiate high would be moderately selective δ agonist | :AH-7921 - Selective μ agonist, with 80% potency of M. distributed as an RC, TRs show that it has very little euphoria, indicating euphoria comes from somewhere else. Perhaps sigma? Other opioids are heavily potentiated by it. Perhaps μ agonism is purely analgesic and high comes from a combination of μ & δ with each multiplying the affect of the other. This indicates ultimate opiate high would be moderately selective δ agonist | ||
− | |||
:Azaprocin - Azaprocin - ~10x potency of M. Faster onset and short duration of actin. Discoved in 1963, never been marketed. The derivative subbed on the phenyl ring with a p-nitro group would be more potent by roughly 2.5. (So 25x potency of M) The open ringed 2,6-dimethylpiperazine analouges would also be active. | :Azaprocin - Azaprocin - ~10x potency of M. Faster onset and short duration of actin. Discoved in 1963, never been marketed. The derivative subbed on the phenyl ring with a p-nitro group would be more potent by roughly 2.5. (So 25x potency of M) The open ringed 2,6-dimethylpiperazine analouges would also be active. | ||
− | |||
:BRL-52537 - Highly potent and selective κ agonist. Neuroprotective. | :BRL-52537 - Highly potent and selective κ agonist. Neuroprotective. | ||
− | |||
:Bromadol (BDPC) - 500-10,000x potency of M. Similar to PCP analogues & -HO bonds within them. | :Bromadol (BDPC) - 500-10,000x potency of M. Similar to PCP analogues & -HO bonds within them. | ||
− | |||
:C-8813 (Thiobromadol) - 591x potency of M. μ agonist & δ antagonist to reduce repiratory depression. Making the drug safer. | :C-8813 (Thiobromadol) - 591x potency of M. μ agonist & δ antagonist to reduce repiratory depression. Making the drug safer. | ||
− | |||
:Ciramadol - Opioid related to PCP, Tramadol & Tapentadol. mixed ant.-ag. for μ, low abuse potential and ceiling on respiratory depression. | :Ciramadol - Opioid related to PCP, Tramadol & Tapentadol. mixed ant.-ag. for μ, low abuse potential and ceiling on respiratory depression. | ||
− | |||
:Enadoline - Highly selective κ agonist. Produces visual distortions, dissociation and of course dysphoria similar to Salvia. | :Enadoline - Highly selective κ agonist. Produces visual distortions, dissociation and of course dysphoria similar to Salvia. | ||
− | |||
:Herkinorin - Analogue of Salvinorin A but the complete opposite. 100x higher μ affinity and 50x lower κ affinity. Also; "does not promote the recruitment of β-arrestin-2 to the intracellular domain of the μ-opioid receptor, or induce receptor internalization". This means Herkinorin may not produce tolerance or dependance. | :Herkinorin - Analogue of Salvinorin A but the complete opposite. 100x higher μ affinity and 50x lower κ affinity. Also; "does not promote the recruitment of β-arrestin-2 to the intracellular domain of the μ-opioid receptor, or induce receptor internalization". This means Herkinorin may not produce tolerance or dependance. | ||
− | |||
:HZ-2 - κ-opioid agonist, same potency as morphine, long duration, high oral BA | :HZ-2 - κ-opioid agonist, same potency as morphine, long duration, high oral BA | ||
− | |||
:ICI-199,441 - high potency, highly selective κ agonist with analgesic effects | :ICI-199,441 - high potency, highly selective κ agonist with analgesic effects | ||
− | |||
:Methopholine - Isoquinilone derivative with same efficacy as codeine. Could produces corneal opacity. Analogues are more potent with 4'-nitromethopholine at 20x codeine. | :Methopholine - Isoquinilone derivative with same efficacy as codeine. Could produces corneal opacity. Analogues are more potent with 4'-nitromethopholine at 20x codeine. | ||
− | |||
:MT-45 - 80% of M. mixed ant.-ag. and mild NMDA antagonist | :MT-45 - 80% of M. mixed ant.-ag. and mild NMDA antagonist | ||
− | |||
:Nortilidine - Equipotency of M. Opioid activity is in (1S,2R) iso, NMDA antagonism is in (1R,2S) iso. Also acts as a DRI. | :Nortilidine - Equipotency of M. Opioid activity is in (1S,2R) iso, NMDA antagonism is in (1R,2S) iso. Also acts as a DRI. | ||
− | |||
:O-Desmethyltramadol - metabolite of Tramadol. Considerably more potent than Tramadol. Both (+) & (-) isomers lose SRI function but (-) retains NRI functionality. RC. | :O-Desmethyltramadol - metabolite of Tramadol. Considerably more potent than Tramadol. Both (+) & (-) isomers lose SRI function but (-) retains NRI functionality. RC. | ||
− | |||
:Salvinorin A - Highly potent κ agonist and even more potent D2 partial agonist. Use in therapy for addiction. | :Salvinorin A - Highly potent κ agonist and even more potent D2 partial agonist. Use in therapy for addiction. | ||
− | |||
:Salvinorin B ethoxymethyl ether - semi-synthetic analogue of Salv. A. Longer duration @ ~3hrs, active at 50ug & 3000x (!) selectivity over μ & δ | :Salvinorin B ethoxymethyl ether - semi-synthetic analogue of Salv. A. Longer duration @ ~3hrs, active at 50ug & 3000x (!) selectivity over μ & δ | ||
− | |||
:Salvinorin B methoxymethyl ether - Similar to ^^ but less selective. 5x potency as Salvinorin A. Deacetylised from Salvinorin A. | :Salvinorin B methoxymethyl ether - Similar to ^^ but less selective. 5x potency as Salvinorin A. Deacetylised from Salvinorin A. | ||
− | |||
:SC-17599 - selective μ agonist with little or no affinity for δ & κ. Potency in between pethidine & morphine. | :SC-17599 - selective μ agonist with little or no affinity for δ & κ. Potency in between pethidine & morphine. | ||
− | |||
:RWJ-394674 - potent and selective δ agonist, however once inside body it is dealkylated to its monodesethyl metabolite RWJ-413216 which is a potent μ agonist with less affinity for δ. δ activity counteracts the respiratory depression the μ causes. Only prominent side effect is sedation (and euphoria!) | :RWJ-394674 - potent and selective δ agonist, however once inside body it is dealkylated to its monodesethyl metabolite RWJ-413216 which is a potent μ agonist with less affinity for δ. δ activity counteracts the respiratory depression the μ causes. Only prominent side effect is sedation (and euphoria!) | ||
− | |||
:TAN-67 - potent and selective δ1 agonist. Has analgesic properties & releases dopamine in the brain. Neuro & cardiac protective properties. | :TAN-67 - potent and selective δ1 agonist. Has analgesic properties & releases dopamine in the brain. Neuro & cardiac protective properties. | ||
− | |||
:Tapentadol - μ & σ agonist & SNRI. Potency in between M & Tram. | :Tapentadol - μ & σ agonist & SNRI. Potency in between M & Tram. | ||
− | |||
:Tifluadom - Benzo derivative but without GABAa agonism. Instead selective κ agonism. | :Tifluadom - Benzo derivative but without GABAa agonism. Instead selective κ agonism. | ||
− | |||
:U-47700 - Overlays betaprodine, 7.5x morphine. | :U-47700 - Overlays betaprodine, 7.5x morphine. | ||
− | |||
:U-50488 - highly selective κ agonist with analgesic effects | :U-50488 - highly selective κ agonist with analgesic effects | ||
− | |||
:U-69,593 - Potent and selective κ1 agonist. Produces; antinociception, anti-inflammation, anxiolysis (low doses), respiratory depression & diuresis. Also inhibits periphery oxytocin secretion. Not sure if hallucinogenic. | :U-69,593 - Potent and selective κ1 agonist. Produces; antinociception, anti-inflammation, anxiolysis (low doses), respiratory depression & diuresis. Also inhibits periphery oxytocin secretion. Not sure if hallucinogenic. | ||
− | |||
:W-15 - 5.4x Morphine. RC. | :W-15 - 5.4x Morphine. RC. | ||
− | |||
:W-18 - 10,000x potency of M, structure abstract from any other drug. These super potent opioids are used in vetenarian practice for tranquilising elephants. | :W-18 - 10,000x potency of M, structure abstract from any other drug. These super potent opioids are used in vetenarian practice for tranquilising elephants. | ||
== Opioid Antagonists and Inverse Agonists == | == Opioid Antagonists and Inverse Agonists == | ||
− | |||
− | |||
(selective δ antagonists may reduce physical addiction without causing w/d if attatched to an opioid) | (selective δ antagonists may reduce physical addiction without causing w/d if attatched to an opioid) | ||
− | |||
− | |||
:Chlornaltrexamine - Irreversible mixed ant.-ag. at μ opioid. 22x more potent than M | :Chlornaltrexamine - Irreversible mixed ant.-ag. at μ opioid. 22x more potent than M | ||
− | |||
:Cyprodime - Selective μ opioid antagonist with no affinity for κ or δ receptors | :Cyprodime - Selective μ opioid antagonist with no affinity for κ or δ receptors | ||
− | |||
:Diprenorphine - Strongest opiate antagonist available. 100x potency of Nalorphine. Used to reverse effects of super-potent opioids. | :Diprenorphine - Strongest opiate antagonist available. 100x potency of Nalorphine. Used to reverse effects of super-potent opioids. | ||
− | |||
:Levallorphan - μ opioid antagonist, when used with opiate, it potentiates it and removes addiction potential or induces withdrawal in addicts. | :Levallorphan - μ opioid antagonist, when used with opiate, it potentiates it and removes addiction potential or induces withdrawal in addicts. | ||
− | |||
:Nalbuphine - mixed ant.-ag. as is common with this class, there occurs analgesia with no addictive properties. | :Nalbuphine - mixed ant.-ag. as is common with this class, there occurs analgesia with no addictive properties. | ||
− | |||
:Naloxazone - Irreversible μ opioid receptor antagonist | :Naloxazone - Irreversible μ opioid receptor antagonist | ||
− | |||
:Naloxonazine - Very Potent Irreversible μ opioid antagonist. dimerizes from Naloxazone under acidic conditions | :Naloxonazine - Very Potent Irreversible μ opioid antagonist. dimerizes from Naloxazone under acidic conditions | ||
− | |||
:Naltrexone - Competitive antagonist at μ & κ receptors, and to a lesser extent, δ. Modulation of the dopaminergic mesolimbic pathway makes it good for countering alcohol dependance as well as Opiate addiction. Blocks the euphoric effects of opioids and is used in rapid detoxification and attenuation of withdrawal. If opiates are used simultaneously, oD may occur. | :Naltrexone - Competitive antagonist at μ & κ receptors, and to a lesser extent, δ. Modulation of the dopaminergic mesolimbic pathway makes it good for countering alcohol dependance as well as Opiate addiction. Blocks the euphoric effects of opioids and is used in rapid detoxification and attenuation of withdrawal. If opiates are used simultaneously, oD may occur. | ||
− | |||
:Samidorphan - selective μ antagonist. potential for addiction treatment. | :Samidorphan - selective μ antagonist. potential for addiction treatment. | ||
== Uncategorised Opioids == | == Uncategorised Opioids == | ||
− | |||
− | |||
:FE 200665 - Is an all D-Amino acid peptide that acts as a restucted K-opioid receptor agnoist. Was dosed at 0.36mg/kg IV. Was compared to 15mg oxycodone. Slightly less than the potency of hydrocodone. Caused Hyperalgesic response in a skin pinch test. Also known as CR665. | :FE 200665 - Is an all D-Amino acid peptide that acts as a restucted K-opioid receptor agnoist. Was dosed at 0.36mg/kg IV. Was compared to 15mg oxycodone. Slightly less than the potency of hydrocodone. Caused Hyperalgesic response in a skin pinch test. Also known as CR665. | ||
− | |||
:SoRI-9409 - mixed μ agonist & δ antagonist. moderate analgesia without development of tolerance. Anti-addictive effects for all dopaminergic drugs. | :SoRI-9409 - mixed μ agonist & δ antagonist. moderate analgesia without development of tolerance. Anti-addictive effects for all dopaminergic drugs. | ||
− | |||
:Synthetic Conotoxin - Snail toxin derived painkiller 1000x potency of morphine. Non-addictive | :Synthetic Conotoxin - Snail toxin derived painkiller 1000x potency of morphine. Non-addictive | ||
==RELATED COMPOUNDS== | ==RELATED COMPOUNDS== | ||
:Amiphenazole - treatment for OD. counteracts respiratory depression. If Morphine-N-oxide is taken on this, M's potency will increase. | :Amiphenazole - treatment for OD. counteracts respiratory depression. If Morphine-N-oxide is taken on this, M's potency will increase. | ||
− | |||
:Chitosan - linear polysaccharide that can give Morphine up to 60% BA intranasally. Powdered & the ratio is 1.3g : 6.7g (morpine : chitosan) | :Chitosan - linear polysaccharide that can give Morphine up to 60% BA intranasally. Powdered & the ratio is 1.3g : 6.7g (morpine : chitosan) | ||
− | |||
:BIMU-8 - NOOTROPIC | :BIMU-8 - NOOTROPIC | ||
:NMDA antagonists - Inhibit development of tolerance to morphine | :NMDA antagonists - Inhibit development of tolerance to morphine | ||
− | |||
:Tezampanel - ANXIOLYTIC | :Tezampanel - ANXIOLYTIC | ||
− | |||
:Ibudilast - NOOTROPIC | :Ibudilast - NOOTROPIC | ||
− | |||
:Nuciferine | :Nuciferine | ||
− | |||
:Tetrahydropalmatine - ANXIOLYTIC | :Tetrahydropalmatine - ANXIOLYTIC | ||
− | |||
:Lofexidine - ANXIOLYTIC | :Lofexidine - ANXIOLYTIC | ||
− | |||
:d & l Phenylalanine (DLPA) - Increases dopamine and endorphin levels, reducing opiate tolerance and even providing an analgesic effect of it's own. | :d & l Phenylalanine (DLPA) - Increases dopamine and endorphin levels, reducing opiate tolerance and even providing an analgesic effect of it's own. | ||
Line 309: | Line 278: | ||
== CCK Antagonists == | == CCK Antagonists == | ||
− | :Proglumide - Acts as a d opioid agonist and non selective CCK antagonist. Enhances analgesia produced by opioids and can prevent or even reverse the development of tolerance | + | :Proglumide - Acts as a d opioid agonist and non selective CCK antagonist.Enhances analgesia produced by opioids and can prevent or even reverse the development of tolerance |
− | + | ||
:Devazepide - No affinity for GABAa, selective CCKa antagonist. | :Devazepide - No affinity for GABAa, selective CCKa antagonist. | ||
− | |||
:Lorglumide - Selective CCKa antagonist for treatment of gastrointestinal problems and some forms of cancer as well as Opioid interacting properties. | :Lorglumide - Selective CCKa antagonist for treatment of gastrointestinal problems and some forms of cancer as well as Opioid interacting properties. | ||
− | |||
== Nocieceptinergic Drugs == | == Nocieceptinergic Drugs == | ||
− | |||
− | |||
(ORL-1 ant. & ag.'s) | (ORL-1 ant. & ag.'s) | ||
− | |||
:J-113,397 - Highly selective ORL-1 antagonist. Prevents development of opiate tolerance, stimulates dopamine release, cognitive enhancer | :J-113,397 - Highly selective ORL-1 antagonist. Prevents development of opiate tolerance, stimulates dopamine release, cognitive enhancer | ||
− | |||
:SB-612,111 - Selective ORL-1 antagonist but several times the potency of ^^ | :SB-612,111 - Selective ORL-1 antagonist but several times the potency of ^^ | ||
− | |||
:MCOPPB - Potent, selective ORL-1 agonist with only moderate affinity for μ, even less for δ & κ. Anxiolytic with no inhibition of memory, motor function or sedation | :MCOPPB - Potent, selective ORL-1 agonist with only moderate affinity for μ, even less for δ & κ. Anxiolytic with no inhibition of memory, motor function or sedation | ||
− | |||
:NNC 63-0532 - Potent, selective ORL-1 agonist. | :NNC 63-0532 - Potent, selective ORL-1 agonist. | ||
− | |||
:Ro64-6198 - Potent, selective ORL-1 agonist with 100x selectivity over others. In rats produced anxiolytic but no anticonvulsant effects. Impairs Short term memory & increases appetite. Reduces analgesic effects of M but no preventing tolerance. In primates it showed analgesic behaviour without respiratory depression. | :Ro64-6198 - Potent, selective ORL-1 agonist with 100x selectivity over others. In rats produced anxiolytic but no anticonvulsant effects. Impairs Short term memory & increases appetite. Reduces analgesic effects of M but no preventing tolerance. In primates it showed analgesic behaviour without respiratory depression. | ||
− | |||
:Menabitan - potent cannabinoid receptor agonist with anti-nociceptive effects | :Menabitan - potent cannabinoid receptor agonist with anti-nociceptive effects | ||
== Enkephalin Potease Inhibitors == | == Enkephalin Potease Inhibitors == | ||
− | |||
:RB-101*** - Inhibits enzymes responsible for breaking down enkephalin (regulates nociceptin). Weak μ & δ affinity and slight σ1. Potentiates opiates, stops withdrawal symptoms, no addiction potential, produces no respiratory depression. Also exerts very potent antidepressant and anxiolytic effects. Not orally active so analogues vv were developed. | :RB-101*** - Inhibits enzymes responsible for breaking down enkephalin (regulates nociceptin). Weak μ & δ affinity and slight σ1. Potentiates opiates, stops withdrawal symptoms, no addiction potential, produces no respiratory depression. Also exerts very potent antidepressant and anxiolytic effects. Not orally active so analogues vv were developed. | ||
− | |||
:RB-120 - Orally active version of the above. | :RB-120 - Orally active version of the above. | ||
− | |||
:RB-3007 - Another Enkeph. PI & Nociceptin antagonist | :RB-3007 - Another Enkeph. PI & Nociceptin antagonist |
└--> Racemic mix of both isomers, embodying their properties.
└--> Racemic mix of both isomers, embodying their properties.
.
(selective δ antagonists may reduce physical addiction without causing w/d if attatched to an opioid)
(ORL-1 ant. & ag.'s)